Invitae Corporation (NYSE:NVTA) Files An 8-K Regulation FD DisclosureItem 7.01
Invitae Corporation (the “Company”) is furnishing the investor presentation attached hereto as Exhibit 99.1 for use on June12, 2018, in which the Company will discuss, among other things, that it has received notification from Medicare of approval for payment of deletion/duplication analysis for certain tests under CPT code 81433 in conjunction with 81432.
| Item 7.01 | Financial Statements and Exhibits. |
(d) Exhibits
Reference is made to the Exhibit Index included with this Current Report on Form 8-K.
EXHIBIT INDEX
| Exhibit No. |
Description |
| 99.1 | Invitae Corporation Investor Presentation. |
Invitae Corp ExhibitEX-99.1 2 d605751dex991.htm EX-99.1 EX-99.1 When the question is genetics,…To view the full exhibit click here
About Invitae Corporation (NYSE:NVTA)
Invitae Corporation (Invitae) utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. The Company offers panels for over 120 conditions in hereditary cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. It has developed an offering that enables healthcare professionals to customize a test and receive test results at requisition.
